Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Breast Cancer

  Free Subscription


27.09.2021

1 Acta Cytol
2 Am J Clin Pathol
2 Am J Surg Pathol
1 Ann Surg
3 Ann Surg Oncol
4 BMC Cancer
3 Br J Cancer
1 Breast Cancer
1 Breast Cancer (Dove Med Press)
12 Breast Cancer Res Treat
2 Breast J
3 Cancer
1 Cancer Chemother Pharmacol
5 Clin Breast Cancer
2 Clin Cancer Res
1 Eur J Cancer
1 Eur J Surg Oncol
2 Eur Radiol
9 Int J Radiat Oncol Biol Phys
3 J Clin Oncol
1 J Surg Oncol
2 Lancet Oncol
1 N Engl J Med
5 NPJ Breast Cancer
2 Oncogene
1 Oncol Rep
1 Oncology
5 PLoS One
1 Radiol Imaging Cancer
1 Radiother Oncol


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Acta Cytol

  1. VERMA P, Sharma R, Sharma N, Gulati A, et al
    Fine-Needle Aspiration Cytology versus Core-Needle Biopsy for Breast Lesions: A Dilemma of Superiority between the Two.
    Acta Cytol. 2021;65:411-416.
    PubMed         Abstract available


    Am J Clin Pathol

  2. WU DY, Spangler AE, de Hoyos A, Vo DT, et al
    Quality of Anatomic Staging of Breast Carcinoma in Hospitals in the United States, With Focus on Measurement of Tumor Dimension.
    Am J Clin Pathol. 2021;156:356-369.
    PubMed         Abstract available

  3. JONES TE, Zou J, Tseng GC, Roy S, et al
    The Utility of Next-Generation Sequencing in Advanced Breast and Gynecologic Cancers.
    Am J Clin Pathol. 2021;156:455-460.
    PubMed         Abstract available


    Am J Surg Pathol

  4. PANG JB, Castles B, Byrne DJ, Button P, et al
    SP142 PD-L1 Scoring Shows High Interobserver and Intraobserver Agreement in Triple-negative Breast Carcinoma But Overall Low Percentage Agreement With Other PD-L1 Clones SP263 and 22C3.
    Am J Surg Pathol. 2021;45:1108-1117.
    PubMed         Abstract available

  5. GRABENSTETTER A, Jungbluth AA, Frosina D, Hoda R, et al
    PD-L1 Expression in Metaplastic Breast Carcinoma Using the PD-L1 SP142 Assay and Concordance Among PD-L1 Immunohistochemical Assays.
    Am J Surg Pathol. 2021;45:1274-1281.
    PubMed         Abstract available


    Ann Surg

  6. GOEL N, Yadegarynia S, Lubarsky M, Choi S, et al
    Racial and Ethnic Disparities in Breast Cancer Survival: Emergence of a Clinically Distinct Hispanic Black Population.
    Ann Surg. 2021;274:e269-e275.
    PubMed         Abstract available


    Ann Surg Oncol

  7. STAHL K, Dodge D, Wong W, Shen C, et al
    ASO Author Reflection: Trimodality Therapy Offers Survival Advantage in Metastatic Male Breast Cancer.
    Ann Surg Oncol. 2021 Sep 16. pii: 10.1245/s10434-021-10790.
    PubMed        

  8. NAGRA NS, Tsangaris E, Means J, Hassett MJ, et al
    Correction to: Time-Driven Activity-Based Costing in Breast Cancer Care Delivery.
    Ann Surg Oncol. 2021 Sep 21. pii: 10.1245/s10434-021-10795.
    PubMed        

  9. BREDBECK BC, Baskin AS, Wang T, Sinco BR, et al
    Incremental Spending Associated with Low-Value Treatments in Older Women with Breast Cancer.
    Ann Surg Oncol. 2021 Sep 23. pii: 10.1245/s10434-021-10807.
    PubMed         Abstract available


    BMC Cancer

  10. ZHANG X, Pang X, Zhang Z, Liu Q, et al
    Co-expression and prognosis analyses of GLUT1-4 and RB1 in breast cancer.
    BMC Cancer. 2021;21:1026.
    PubMed         Abstract available

  11. STURKEN C, Mobus V, Milde-Langosch K, Schmatloch S, et al
    Correction to: TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer.
    BMC Cancer. 2021;21:1024.
    PubMed        

  12. JAKOBSEN M, Kolodziejczyk C, Jensen MS, Poulsen PB, et al
    Cardiovascular disease in women with breast cancer - a nationwide cohort study.
    BMC Cancer. 2021;21:1040.
    PubMed         Abstract available

  13. RAGALA MEA, El Hilaly J, Amaadour L, Omari M, et al
    Validation of Mini-Mental Adjustment to Cancer scale in a Moroccan sample of breast cancer women.
    BMC Cancer. 2021;21:1042.
    PubMed         Abstract available


    Br J Cancer

  14. WALLER CF, Mobius J, Fuentes-Alburo A
    Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice.
    Br J Cancer. 2021;124:1346-1352.
    PubMed         Abstract available

  15. SESTAK I, Blake G, Patel R, Cuzick J, et al
    Off-treatment bone mineral density changes in postmenopausal women receiving anastrozole for 5 years: 7-year results from the IBIS-II prevention trial.
    Br J Cancer. 2021 Jan 22. pii: 10.1038/s41416-020-01228.
    PubMed         Abstract available

  16. PARK B, Kim S, Kim H, Cha C, et al
    Associations between obesity, metabolic health, and the risk of breast cancer in East Asian women.
    Br J Cancer. 2021 Sep 22. pii: 10.1038/s41416-021-01540.
    PubMed         Abstract available


    Breast Cancer

  17. KAMIYA S, Satake H, Hayashi Y, Ishigaki S, et al
    Features from MRI texture analysis associated with survival outcomes in triple-negative breast cancer patients.
    Breast Cancer. 2021 Sep 16. pii: 10.1007/s12282-021-01294.
    PubMed         Abstract available


    Breast Cancer (Dove Med Press)

  18. YAP KM, Sekar M, Seow LJ, Gan SH, et al
    Mangifera indica (Mango): A Promising Medicinal Plant for Breast Cancer Therapy and Understanding Its Potential Mechanisms of Action.
    Breast Cancer (Dove Med Press). 2021;13:471-503.
    PubMed         Abstract available


    Breast Cancer Res Treat

  19. VAN BELLE H, Hurvitz SA, Gilbar PJ, Wildiers H, et al
    Systematic review and meta-analysis of febrile neutropenia risk with TCH(P) in HER2-positive breast cancer.
    Breast Cancer Res Treat. 2021 Sep 17. pii: 10.1007/s10549-021-06387.
    PubMed         Abstract available

  20. CAPELLEN CC, Ortega-Rodas J, Morwitzer MJ, Tofilau HMN, et al
    Hyperglycemic conditions proliferate triple negative breast cancer cells: role of ornithine decarboxylase.
    Breast Cancer Res Treat. 2021 Sep 16. pii: 10.1007/s10549-021-06388.
    PubMed         Abstract available

  21. AUGUSTINSSON A, Nilsson MP, Ellberg C, Kristoffersson U, et al
    Genetic testing in women with early-onset breast cancer: a Traceback pilot study.
    Breast Cancer Res Treat. 2021 Sep 16. pii: 10.1007/s10549-021-06351.
    PubMed         Abstract available

  22. FUKADA I, Ito Y, Kondo N, Ohtani S, et al
    A phase II study of sequential treatment with anthracycline and taxane followed by eribulin in patients with HER2-negative, locally advanced breast cancer (JBCRG-17).
    Breast Cancer Res Treat. 2021 Sep 23. pii: 10.1007/s10549-021-06396.
    PubMed         Abstract available

  23. TEJERA D, Rana M, Basik M, Boileau JF, et al
    Population-based analysis of non-operative management and treatment patterns in older women with estrogen receptor-positive breast cancer.
    Breast Cancer Res Treat. 2021 Sep 20. pii: 10.1007/s10549-021-06393.
    PubMed         Abstract available

  24. ARIAS-PULIDO H, Cimino-Mathews AM, Chaher N, Qualls CR, et al
    Differential effects of CD20+ B cells and PD-L1+ immune cells on pathologic complete response and outcome: comparison between inflammatory breast cancer and locally advanced breast cancer patients.
    Breast Cancer Res Treat. 2021 Sep 20. pii: 10.1007/s10549-021-06391.
    PubMed         Abstract available

  25. LAPIDARI P, Djehal N, Havas J, Gbenou A, et al
    Determinants of use of oral complementary-alternative medicine among women with early breast cancer: a focus on cancer-related fatigue.
    Breast Cancer Res Treat. 2021 Sep 24. pii: 10.1007/s10549-021-06394.
    PubMed         Abstract available

  26. BAHRAMI N, Jabeen S, Tahiri A, Sauer T, et al
    Lack of cross-resistance between non-steroidal and steroidal aromatase inhibitors in breast cancer patients: the potential role of the adipokine leptin.
    Breast Cancer Res Treat. 2021 Sep 23. pii: 10.1007/s10549-021-06399.
    PubMed         Abstract available

  27. YANG Y, Pan L, Shao Z
    Trend and survival benefit of contralateral prophylactic mastectomy among men with stage I-III unilateral breast cancer in the USA, 1998-2016.
    Breast Cancer Res Treat. 2021 Sep 23. pii: 10.1007/s10549-021-06397.
    PubMed         Abstract available

  28. MALIN D, Lee Y, Chepikova O, Strekalova E, et al
    Methionine restriction exposes a targetable redox vulnerability of triple-negative breast cancer cells by inducing thioredoxin reductase.
    Breast Cancer Res Treat. 2021 Sep 22. pii: 10.1007/s10549-021-06398.
    PubMed         Abstract available

  29. CAZZANIGA ME, Vallini I, Montagna E, Amoroso D, et al
    Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study.
    Breast Cancer Res Treat. 2021 Sep 21. pii: 10.1007/s10549-021-06375.
    PubMed         Abstract available

  30. DAI MS, Feng YH, Chen SW, Masuda N, et al
    Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two
    Breast Cancer Res Treat. 2021 Sep 23. pii: 10.1007/s10549-021-06313.
    PubMed         Abstract available


    Breast J

  31. HA M, Ngaage LM, Klein M, Yang A, et al
    Contralateral prophylactic mastectomy in the setting of breast cancer diagnosis and their insurance coverage in the United States.
    Breast J. 2021 Sep 15. doi: 10.1111/tbj.14280.
    PubMed         Abstract available

  32. KITTAKA N, Nakajima S, Hatano T, Seto Y, et al
    Axillary management based on American college of surgeons oncology group Z0011 criteria makes it possible to omit intraoperative diagnosis of sentinel lymph nodes in early breast cancer patients.
    Breast J. 2021 Sep 23. doi: 10.1111/tbj.14291.
    PubMed         Abstract available


    Cancer

  33. NABI J, Tully KH, Cole AP, Marchese M, et al
    Access denied: The relationship between patient insurance status and access to high-volume hospitals.
    Cancer. 2021;127:577-585.
    PubMed         Abstract available

  34. SIMON MS, Hastert TA, Barac A, Banack HR, et al
    Cardiometabolic risk factors and survival after cancer in the Women's Health Initiative.
    Cancer. 2021;127:598-608.
    PubMed         Abstract available

  35. TAMI-MAURY IM, Liao Y, Rangel ML, Gatus LA, et al
    Active living after cancer: Adaptation and evaluation of a community-based physical activity program for minority and medically underserved breast cancer survivors.
    Cancer. 2021 Sep 23. doi: 10.1002/cncr.33904.
    PubMed         Abstract available


    Cancer Chemother Pharmacol

  36. WANG B, Deng R, Hennig S, Badovinac Crnjevic T, et al
    Correction to: Population pharmacokinetic and exploratory exposure-response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study.
    Cancer Chemother Pharmacol. 2021 Sep 24. pii: 10.1007/s00280-021-04342.
    PubMed        


    Clin Breast Cancer

  37. KJOE PRLM, van der Wall E, Schagen SB
    Endocrine Therapy With or Without CDK4/6 Inhibitors in Women With Hormone-receptor Positive Breast Cancer: What do we Know About the Effects on Cognition?
    Clin Breast Cancer. 2021 Aug 14. pii: S1526-8209(21)00239.
    PubMed         Abstract available

  38. JIANG Y, Xie Q, Chen R
    Breast Cancer Incidence and Mortality in Relation to Hormone Replacement Therapy Use Among Postmenopausal Women: Results From a Prospective Cohort Study.
    Clin Breast Cancer. 2021 Jun 26. pii: S1526-8209(21)00171.
    PubMed         Abstract available

  39. BORMAN P, Yaman A, Yasrebi S, Pinar Inanli A, et al
    Combined Complete Decongestive Therapy Reduces Volume and Improves Quality of Life and Functional Status in Patients With Breast Cancer-Related Lymphedema.
    Clin Breast Cancer. 2021 Aug 19. pii: S1526-8209(21)00242.
    PubMed         Abstract available

  40. ZHANG S, Cui T, Duan Y, Zhang H, et al
    Radix Tetrastigma Extracts Enhance the Chemosensitivity in Triple-Negative Breast Cancer Via Inhibiting PI3K/Akt/mTOR-Mediated Autophagy.
    Clin Breast Cancer. 2021 Aug 4. pii: S1526-8209(21)00203.
    PubMed         Abstract available

  41. ALMALKI HS, Lim A, Allen JC, Teo SY, et al
    Usefulness of supplementary ultrasound surveillance in the detection of a second breast cancer in patients with ductal carcinoma in situ.
    Clin Breast Cancer. 2021 Aug 20. pii: S1526-8209(21)00243.
    PubMed         Abstract available


    Clin Cancer Res

  42. PIZZAMIGLIO S, Ciniselli CM, Triulzi T, Gargiuli C, et al
    Integrated molecular and immune phenotype of HER2-positive breast cancer and response to neoadjuvant therapy: a NeoALTTO exploratory analysis.
    Clin Cancer Res. 2021 Sep 21. pii: 1078-0432.CCR-21-1600.
    PubMed         Abstract available

  43. MARQUEZ-ORTIZ RA, Contreras-Zarate MJ, Tesic V, Alvarez-Eraso KL, et al
    IL13Ralpha2 promotes proliferation and outgrowth of breast cancer brain metastases.
    Clin Cancer Res. 2021 Sep 20. pii: 1078-0432.CCR-21-0361.
    PubMed         Abstract available


    Eur J Cancer

  44. LI H, Wang J, Yi Z, Li C, et al
    CDK12 inhibition enhances sensitivity of HER2+ breast cancers to HER2-tyrosine kinase inhibitor via suppressing PI3K/AKT.
    Eur J Cancer. 2021;145:92-108.
    PubMed         Abstract available


    Eur J Surg Oncol

  45. LORENTZEN T, Heidemann LN, Moller S, Bille C, et al
    Impact of neoadjuvant chemotherapy on surgical complications in breast cancer: A systematic review and meta-analysis.
    Eur J Surg Oncol. 2021 Sep 16. pii: S0748-7983(21)00733.
    PubMed         Abstract available


    Eur Radiol

  46. TAHIR E, Azar M, Shihada S, Seiffert K, et al
    Myocardial injury detected by T1 and T2 mapping on CMR predicts subsequent cancer therapy-related cardiac dysfunction in patients with breast cancer treated by epirubicin-based chemotherapy or left-sided RT.
    Eur Radiol. 2021 Sep 18. pii: 10.1007/s00330-021-08260.
    PubMed         Abstract available

  47. BOISSERIE-LACROIX M, Doutriaux-Dumoulin I, Chopier J, Boyer B, et al
    Diagnostic accuracy of breast MRI for patients with suspicious nipple discharge and negative mammography and ultrasound: a prospective study.
    Eur Radiol. 2021;31:7783-7791.
    PubMed         Abstract available


    Int J Radiat Oncol Biol Phys

  48. JACOBSON G, Lawrence YR, Appel S, Weiss I, et al
    Benefits of Continuous Positive Airway Pressure (CPAP) During Radiation Therapy: A Prospective Trial.
    Int J Radiat Oncol Biol Phys. 2021;110:1466-1472.
    PubMed         Abstract available

  49. BRADLEY JA, Strauss JB, Bellon JR
    Postmastectomy Bolus: Urban Legend or Sound Practice?
    Int J Radiat Oncol Biol Phys. 2021;110:1370-1372.
    PubMed        

  50. VAN VELZEN SGM, Bruns S, Wolterink JM, Leiner T, et al
    AI-based quantification of planned radiotherapy dose to cardiac structures and coronary arteries in breast cancer patients.
    Int J Radiat Oncol Biol Phys. 2021 Sep 18. pii: S0360-3016(21)02792.
    PubMed         Abstract available

  51. MANUKIAN G, Kivolowitz C, DeAngelis T, Shastri AA, et al
    Caloric Restriction Impairs Regulatory T cells Within the Tumor Microenvironment After Radiation and Primes Effector T cells.
    Int J Radiat Oncol Biol Phys. 2021;110:1341-1349.
    PubMed         Abstract available

  52. NICHOL A, Narinesingh D, Raman S, Germain F, et al
    The Effect of Bolus on Local Control for Patients Treated With Mastectomy and Radiation Therapy.
    Int J Radiat Oncol Biol Phys. 2021;110:1360-1369.
    PubMed         Abstract available

  53. PURSWANI JM, Oh C, Jaros B, Sandigursky S, et al
    Breast Conservation in Women with Autoimmune Disease: The Role of Active Autoimmune Disease and Hypofractionation on Acute and Late Toxicity in a Case-Controlled Series.
    Int J Radiat Oncol Biol Phys. 2021;110:783-791.
    PubMed         Abstract available

  54. SMALL W JR, Pugh SL, Wagner LI, Kirshner J, et al
    Psychological Treatment for Patients Receiving Radiation: Results of NRG Oncology/RTOG 0841.
    Int J Radiat Oncol Biol Phys. 2021;110:962-972.
    PubMed         Abstract available

  55. PRASANNA PG, Rawojc K, Guha C, Buchsbaum JC, et al
    Normal Tissue Injury Induced by Photon and Proton Therapies: Gaps and Opportunities.
    Int J Radiat Oncol Biol Phys. 2021;110:1325-1340.
    PubMed         Abstract available

  56. BOSMA SCJ, van der Leij F, Elkhuizen PHM, Vreeswijk S, et al
    Evaluation of Early Response to Preoperative Accelerated Partial Breast Irradiation (PAPBI) by Histopathology, Magnetic Resonance Imaging, and 18F-fluorodexoyglucose Positron Emission Tomography/Computed Tomography (FDG PET/CT).
    Int J Radiat Oncol Biol Phys. 2021;110:1151-1158.
    PubMed         Abstract available


    J Clin Oncol

  57. SHIMOI T, Noguchi E, Sudo K, Chua YJ, et al
    Critical Appraisal of Adjuvant Platinum-Based Chemotherapy for Basal Subtype Triple-Negative Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy.
    J Clin Oncol. 2021 Sep 23:JCO2101537. doi: 10.1200/JCO.21.01537.
    PubMed        

  58. SHIMANUKI Y, Shimomura A, Yoshimura K, Terakado H, et al
    Are Platinum Drugs Ineffective for Triple-Negative Breast Cancer With Residual Invasive Disease After Neoadjuvant Chemotherapy?
    J Clin Oncol. 2021 Sep 23:JCO2101757. doi: 10.1200/JCO.21.01757.
    PubMed        

  59. HENRY NL, Kim S, Hays RD, Diniz MA, et al
    Toxicity Index, Patient-Reported Outcomes, and Early Discontinuation of Endocrine Therapy for Breast Cancer Risk Reduction in NRG Oncology/NSABP B-35.
    J Clin Oncol. 2021 Sep 23:JCO2100910. doi: 10.1200/JCO.21.00910.
    PubMed         Abstract available


    J Surg Oncol

  60. MILLER TJ, Remington AC, Nguyen DH, Gurtner GC, et al
    Preoperative beta-lactam antibiotic prophylaxis is superior to bacteriostatic alternatives in immediate expander-based breast reconstruction.
    J Surg Oncol. 2021;124:722-730.
    PubMed         Abstract available


    Lancet Oncol

  61. YUNG RL, Davidson NE
    Optimal adjuvant endocrine therapy for breast cancer.
    Lancet Oncol. 2021 Sep 15. pii: S1470-2045(21)00420.
    PubMed        

  62. DEL MASTRO L, Mansutti M, Bisagni G, Ponzone R, et al
    Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trial.
    Lancet Oncol. 2021 Sep 15. pii: S1470-2045(21)00352.
    PubMed         Abstract available


    N Engl J Med

  63. BOSE R, Ma CX
    Breast Cancer, HER2 Mutations, and Overcoming Drug Resistance.
    N Engl J Med. 2021;385:1241-1243.
    PubMed        


    NPJ Breast Cancer

  64. VOS H, Lambein K, Richard F, Marien B, et al
    Comparison of the tumor immune microenvironment of primary hormone receptor-negative HER2-positive and triple negative breast cancer.
    NPJ Breast Cancer. 2021;7:128.
    PubMed         Abstract available

  65. GOMBOS A, Venet D, Ameye L, Vuylsteke P, et al
    FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer.
    NPJ Breast Cancer. 2021;7:125.
    PubMed         Abstract available

  66. INASU M, Bendahl PO, Ferno M, Malmstrom P, et al
    High CYP27A1 expression is a biomarker of favorable prognosis in premenopausal patients with estrogen receptor positive primary breast cancer.
    NPJ Breast Cancer. 2021;7:127.
    PubMed         Abstract available

  67. RADOSEVIC-ROBIN N, Selenica P, Zhu Y, Won HH, et al
    Recurrence biomarkers of triple negative breast cancer treated with neoadjuvant chemotherapy and anti-EGFR antibodies.
    NPJ Breast Cancer. 2021;7:124.
    PubMed         Abstract available

  68. SHAH H, Pang L, Qian S, Sathish V, et al
    Iminodibenzyl induced redirected COX-2 activity inhibits breast cancer progression.
    NPJ Breast Cancer. 2021;7:122.
    PubMed         Abstract available


    Oncogene

  69. LIU Z, Sang X, Wang M, Liu Y, et al
    Melatonin potentiates the cytotoxic effect of Neratinib in HER2(+) breast cancer through promoting endocytosis and lysosomal degradation of HER2.
    Oncogene. 2021 Sep 23. pii: 10.1038/s41388-021-02015.
    PubMed         Abstract available

  70. VAFAIZADEH V, Buechel D, Rubinstein N, Kalathur RKR, et al
    The interactions of Bcl9/Bcl9L with beta-catenin and Pygopus promote breast cancer growth, invasion, and metastasis.
    Oncogene. 2021 Sep 20. pii: 10.1038/s41388-021-02016.
    PubMed         Abstract available


    Oncol Rep

  71. FENG X, Cao A, Qin T, Zhang Q, et al
    Abnormally elevated ubiquilin1 expression in breast cancer regulates metastasis and stemness via AKT signaling.
    Oncol Rep. 2021;46.
    PubMed         Abstract available


    Oncology

  72. DE GREGORIO A, Friedl TWP, Hering E, Widschwendter P, et al
    Ki67 as Proliferative Marker in Patients with Early Breast Cancer and Its Association with Clinicopathological Factors.
    Oncology. 2021 Sep 14:1-10. doi: 10.1159/000517490.
    PubMed         Abstract available


    PLoS One

  73. MEKONEN S, Ibrahim M, Astatkie H, Abreha A, et al
    Exposure to organochlorine pesticides as a predictor to breast cancer: A case-control study among Ethiopian women.
    PLoS One. 2021;16:e0257704.
    PubMed         Abstract available

  74. YOSHIKAWA K, Ishida M, Yanai H, Tsuta K, et al
    Immunohistochemical comparison of three programmed death-ligand 1 (PD-L1) assays in triple-negative breast cancer.
    PLoS One. 2021;16:e0257860.
    PubMed         Abstract available

  75. OLAYA-GALAN NN, Salas-Cardenas SP, Rodriguez-Sarmiento JL, Ibanez-Pinilla M, et al
    Risk factor for breast cancer development under exposure to bovine leukemia virus in Colombian women: A case-control study.
    PLoS One. 2021;16:e0257492.
    PubMed         Abstract available

  76. CASELLI E, Pelliccia C, Teti V, Bellezza G, et al
    Looking for more reliable biomarkers in breast cancer: Comparison between routine methods and RT-qPCR.
    PLoS One. 2021;16:e0255580.
    PubMed         Abstract available

  77. CIRIA-SUAREZ L, Jimenez-Fonseca P, Palacin-Lois M, Antonanzas-Basa M, et al
    Breast cancer patient experiences through a journey map: A qualitative study.
    PLoS One. 2021;16:e0257680.
    PubMed         Abstract available


    Radiol Imaging Cancer

  78. WAHAB RA, Lee SJ, Mulligan ME, Zhang B, et al
    Upgrade Rate of Pure Flat Epithelial Atypia Diagnosed at Core Needle Biopsy: A Systematic Review and Meta-Analysis.
    Radiol Imaging Cancer. 2021;3:e200116.
    PubMed         Abstract available


    Radiother Oncol

  79. FRANCESCHINI D, Fogliata A, Spoto R, Dominici L, et al
    Long term results of a phase II trial of hypofractionated adjuvant radiotherapy for early-stage breast cancer with volumetric modulated arc therapy and simultaneous integrated boost.
    Radiother Oncol. 2021 Sep 16. pii: S0167-8140(21)06726.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: